Explore News By Topic

08/01/2018

The Prostate Cancer Foundation Appoints Christine Jones as Chief Operating Officer

SANTA MONICA, Calif., August 1, 2018 – The Prostate Cancer Foundation (PCF) today announced that Christine Jones has been appointed Chief Operating Officer effective immediately reporting to Jonathan W. Simons, MD, President and Chief Executive Officer (CEO). In this role, Ms. Jones will contribute to the strategic growth of the... Read More

07/19/2018

Genomic Landscape of Metastatic Prostate Cancer Unveiled in New Study

A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease. As reported in the July 19, 2018 issue of Cell, a team led by investigators at UC... Read More

07/17/2018

NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men

The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun. The $26.5 million study is called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress. It will... Read More

07/13/2018

BREAKING NEWS: FDA Approves Enzalutamide (Xtandi) for Non-Metastatic Castration-Resistant Prostate Cancer

July 13, 2018 – Today the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC).  Non-metastatic CRPC is a clinical state in which PSA levels begin to rise in patients being treated with androgen deprivation therapy (ADT), but metastases are... Read More

07/11/2018

Deadly Form of Advanced Prostate Cancer is Common, Calls for Distinct Treatment

Original article issued by UCSF News. A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer. Previously, it... Read More

07/10/2018

Tumors Grown in the Lab Provide Insights on Rare Prostate Cancer

Original article issued by Weill Cornell Medicine. Growing miniature tumors from patient’s cells in the laboratory may help scientists personalize treatments for those with a rare form of prostate cancer, according a study by Weill Cornell Medicine and NewYork-Presbyterian scientists. Patients with prostate cancer often receive therapies that reduce levels... Read More

06/26/2018

How Your Spit May Help Doctors Diagnose Prostate Cancer

Original article issued by Healthline. It might seem inconceivable that a simple saliva test can tell you your chances of developing cancer. But evidently it can. And the reason is crude but simple: Your genetic makeup can be found in your spit. Scientists are now able to extract DNA from cells... Read More

06/25/2018

Researchers find prostate cancer drug byproduct can fuel cancer cells

Original press release issued by: Cleveland Clinic. A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic. The findings may provide important information for identifying which patients potentially fare better when treated with... Read More

06/22/2018

Crystal Ball for Predicting Cancer Treatment Response: Your Poop?

What does the population of bacteria in your gut (called the gut “microbiome”) have to do with prostate cancer? Just how important is this gut flora, or bacteria, anyway? It’s not even in the prostate! Let’s look at the second question first. How important is your gut bacteria? It’s very... Read More

06/14/2018

New Study Identifies Another Opportunity for Precision Immunotherapy in Prostate Cancer

A new Prostate Cancer Foundation (PCF)-funded study published today in the scientific journal Cell has identified a new subtype of advanced prostate cancer – one which may be treatable with checkpoint immunotherapy, a type of treatment that can produce long-term remissions and even cures in many cancer types, but has... Read More